*ST太安(002433) - 2021 Q3 - 季度财报

Revenue and Profit - Revenue for Q3 2021 was CNY 206,805,526.01, a decrease of 76.65% compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2021 was CNY 33,130,398.87, an increase of 135.05% year-on-year[4] - Net profit attributable to shareholders after deducting non-recurring gains and losses was CNY -25,315,715.81, a decrease of 390.71% compared to the same period last year[4] - The company reported a significant increase in net profit for the year-to-date, up 1,263.81% to CNY 552,732,561.75, primarily due to gains from the transfer of subsidiaries[9] - Basic earnings per share for Q3 2021 were CNY 0.04, a 100.00% increase year-on-year[4] - Total revenue decreased by ¥1,077,609,656.13, a decline of 42.70%, primarily due to the transfer of subsidiary Guangdong Kang Aido Digital Health Technology Co., Ltd.[17] - Net profit attributable to shareholders increased by ¥512,204,092.72, a growth of 1263.81%, mainly due to investment income from the transfer of equity in Kang Aido and Hongyu Trading Co., Ltd.[20] - Net profit for the period reached CNY 546,019,588.39, significantly up from CNY 49,015,470.84 in the previous year, marking an increase of 1007.5%[36] - Earnings per share (EPS) for the quarter was CNY 0.72, compared to CNY 0.05 in the same quarter last year[37] - The company reported investment income of CNY 754,923,301.87, a substantial increase from CNY 26,625,006.14 in the previous year[36] Cash Flow and Liquidity - Cash flow from operating activities for the year-to-date was CNY 561,086,757.79, an increase of 356.78% year-on-year[4] - The company experienced a 71.06% decrease in cash and cash equivalents compared to the end of the previous year, primarily due to repayment of bank loans[12] - Operating cash inflow decreased by ¥1,543,354,843.37, a decline of 45.10%, mainly due to decreased sales revenue[22] - Net cash flow from operating activities increased by ¥779,595,234.03, a growth of 356.78%, primarily due to reduced procurement of medicines and expenses[23] - Cash inflow from investment activities rose by CNY 526,925,430.53, reflecting a year-on-year increase of 969.28%[24] - Cash outflow from investment activities decreased by CNY 105,366,023.30, a year-on-year decline of 81.39%[25] - Net cash flow from financing activities decreased by CNY 1,349,953,948.94, a year-on-year drop of 709.24%[26] - Cash and cash equivalents net increase amounted to CNY 61,934,848.12, representing a year-on-year growth of 59.97%[26] - The net cash flow from operating activities for Q3 2021 was ¥561,086,757.79, a significant improvement compared to a negative cash flow of ¥218,508,476.24 in the same period last year[40] - Total cash inflow from investment activities was ¥581,287,960.53, compared to ¥54,362,530.00 in Q3 2020, indicating a strong increase in investment returns[40] - The net cash flow from financing activities was negative at -¥1,159,616,541.22, a decline from a positive cash flow of ¥190,337,407.72 in the previous year[41] - The total cash and cash equivalents at the end of Q3 2021 stood at ¥59,389,749.83, down from ¥75,507,593.49 at the end of Q3 2020[41] - The company reported cash outflows for debt repayment amounting to ¥2,338,198,102.32, significantly higher than the previous year's figure of ¥684,486,346.27[41] - The cash paid for purchasing goods and services was ¥777,029,197.13, compared to ¥2,583,988,166.72 in the same quarter last year, reflecting a decrease in operational expenses[40] - The cash paid to employees was ¥133,726,820.59, slightly lower than ¥152,467,198.05 in Q3 2020, indicating cost management efforts[40] Assets and Liabilities - Total assets at the end of the reporting period were CNY 8,184,529,600.73, a decrease of 9.83% from the end of the previous year[5] - Shareholders' equity attributable to the parent company increased by 10.25% to CNY 5,774,453,992.59 compared to the end of the previous year[5] - Total current assets as of September 30, 2021, were CNY 4,538,056,590.40, down from CNY 4,669,460,347.34 at the end of 2020[32] - Total liabilities amounted to CNY 2,314,341,230.13, down from CNY 3,656,023,097.44 year-on-year[34] - Total equity attributable to shareholders reached CNY 5,774,453,992.59, an increase from CNY 5,237,831,865.89 in the previous year[34] - The company’s total assets were reported at CNY 8,184,529,600.73, a decrease from CNY 9,077,058,813.52 year-on-year[34] - Current liabilities decreased by ¥1,640,136,815.02, a decline of 46.02%, mainly due to repayment of due bank loans and company bonds[15] - Long-term payables increased by ¥283,986,903.72, a growth of 1455.53%, mainly due to borrowing from China Orient Asset Management Co., Ltd.[15] Other Financial Information - The company reported a 97.99% decrease in development expenses due to the loss of control over a subsidiary[13] - Contract liabilities increased by ¥53,151,824.86, a growth of 116.92%, mainly due to an increase in advance payments received[14] - Employee compensation payable decreased by ¥13,154,430.72, a decline of 91.79%, primarily due to the loss of control over subsidiary Guangdong Kang Aido Digital Health Technology Co., Ltd.[14] - Tax payable increased by ¥22,570,726.66, a growth of 84.29%, mainly due to increased income tax from the transfer of equity in Guangdong Kang Aido Digital Health Technology Co., Ltd.[14] - Other payables increased by ¥191,901,157.63, a growth of 222.05%, primarily due to increased transactions with other units[14] - The company reduced fixed asset investments, leading to a decrease in cash outflow for fixed asset purchases by CNY 117,866,023.30, a decline of 91.04%[24] - The company repaid bank loans and bonds, resulting in a cash outflow increase of CNY 1,647,127,481.00, a year-on-year growth of 200.68%[25] Compliance and Reporting - The company did not undergo an audit for the Q3 2021 report, which may affect the reliability of the financial data presented[42] - The company has not applied the new leasing standards for the financial statements, indicating a potential area for future compliance adjustments[42] - The report was published on October 30, 2021, providing timely insights into the company's financial performance for stakeholders[43]